Showing results (21-30 of 104) with videos related to
Sort By:
Pageof 11
Bone Marrow Transplantation|June 29, 2000
Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overviewN M Blijlevens, J P Donnelly, B E De PauwAnnals of Hematology|October 1, 1991
Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patientsI R Nováková, J P Donnelly, B E de PauwIdrugs : the Investigational Drugs Journal|August 27, 2005
Voriconazole (Pfizer ltd)P E Verweij, B E de Pauw, J F MeisHematology (Amsterdam, Netherlands)|July 16, 2016
Regional Variations in the Further Management of Neutropenic Patients already Receiving Empirical Antimicrobial TherapyJ P Donnelly, B E De Pauw, E E Lane-AllmanMedical Mycology|March 29, 2001
Reliability of clinical research on invasive fungal infections: a systematic review of the literatureS Ascioglu, B E de Pauw, J P Donnelly, et al.Bone Marrow Transplantation|March 24, 2005
Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplantN M A Blijlevens, J P Donnelly, B E de PauwEuropean Journal of Haematology|March 1, 1987
Drug-induced skin reactions in patients with acute non-lymphocytic leukaemiaC Verhagen, L J Stalpers, B E de Pauw, et al.Journal of Internal Medicine. Supplement|January 1, 1997
Empirical and subsequent use of antibacterial agents in the febrile neutropenic patientB E De Pauw, J M Raemaekers, T Schattenberg, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 1, 1988
Ceftazidime sodium carbonate versus ceftazidime arginine as empirical monotherapy in febrile neutropenic patientsC Verhagen, B E De Pauw, K J Williams, et al.The Netherlands Journal of Medicine|February 1, 1990
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromesB M Bär, T de Witte, B E de Pauw, et al.Pageof 11